Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,379,800
  • Shares Outstanding, K 2,443,530
  • Annual Sales, $ 16,967 M
  • Annual Income, $ 5,792 M
  • 36-Month Beta 0.69
  • Price/Sales 6.75
  • Price/Cash Flow 17.47
  • Price/Book 15.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.28 +5.79%
on 06/12/18
48.30 -3.02%
on 05/23/18
-1.78 (-3.66%)
since 05/22/18
3-Month
44.28 +5.79%
on 06/12/18
50.63 -7.49%
on 04/10/18
-2.37 (-4.82%)
since 03/22/18
52-Week
41.03 +14.16%
on 07/27/17
58.37 -19.75%
on 01/23/18
+3.17 (+7.26%)
since 06/22/17

Most Recent Stories

More News
Tresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycemia versus insulin Toujeo® in real-world evidence study

Adults with type 2 diabetes treated with Tresiba(®) (insulin degludec injection) had a significant reduction in HbA(1c) and a 30 per cent lower rate of hypoglycemic episodes compared with those treated...

NVO : 46.84 (+0.95%)
Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

PTCT : 36.01 (-0.83%)
FMI : 136.70 (+0.22%)
NVO : 46.84 (+0.95%)
RHHBY : 27.7700 (+2.51%)
PFE : 36.51 (+0.58%)
GSK : 40.89 (+0.20%)
BMY : 55.14 (+2.22%)
Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study

Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.

AGLE : 10.72 (+2.29%)
AZN : 35.06 (-0.26%)
NVO : 46.84 (+0.95%)
LLY : 85.92 (-0.17%)
Emisphere Development Update

Novo Nordisk announced yesterday the completion and results of the phase 3a trials, PIONEER 4 and 7, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment...

EMIS : 2.5700 (+1.58%)
NVO : 46.84 (+0.95%)
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.

AGLE : 10.72 (+2.29%)
NVO : 46.84 (+0.95%)
ILMN : 282.65 (-1.19%)
ANIP : 68.08 (+0.74%)
Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza(R) and sitagliptin in the PIONEER 4 and 7 trials

Bagsvaerd, Denmark, 20 June 2018 - Novo Nordisk today announced the successful completion and headline results of the phase 3a trials PIONEER 4 comparing oral semaglutide as a treatment for adults with...

NVO : 46.84 (+0.95%)
LLY vs. NVO: Which Stock Should Value Investors Buy Now?

LLY vs. NVO: Which Stock Is the Better Value Option?

NVO : 46.84 (+0.95%)
LLY : 85.92 (-0.17%)
Novo Nordisk to present 39 abstracts at the 78th Annual American Diabetes Association Scientific Sessions

Novo Nordisk today announced that the company will share data from 39 abstracts discussing a breadth of new clinical, real-world and patient perspectives data across its portfolio of pipeline and marketed...

NVO : 46.84 (+0.95%)
Global Smart Insulin Pens Market Analysis & Industry Forecast 2017-2023, With an Expected CAGR of 10.7% - ResearchAndMarkets.com

The "Smart Insulin Pens Market by Type - Global Opportunity Analysis and Industry Forecast, 2017-2023" report has been added to ResearchAndMarkets.com's offering. The global smart...

NVO : 46.84 (+0.95%)
LLY : 85.92 (-0.17%)
New Research: Key Drivers of Growth for ObsEva SA, Gran Tierra Energy, Novo Nordisk A/S, HudBay Minerals, Tecnoglass, and Endeavour Silver -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ObsEva SA (NASDAQ:OBSV), Gran...

OBSV : 14.71 (-1.47%)
HBM : 6.10 (+2.52%)
NVO : 46.84 (+0.95%)
GTE : 3.23 (+2.22%)
EXK : 3.21 (+1.58%)
TGLS : 8.72 (-0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 47.34
1st Resistance Point 47.09
Last Price 46.84
1st Support Level 46.50
2nd Support Level 46.16

See More

52-Week High 58.37
Fibonacci 61.8% 51.75
Fibonacci 50% 49.70
Fibonacci 38.2% 47.65
Last Price 46.84
52-Week Low 41.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar